Mylan will pay the Department of Justice $465 million in a settlement over its pricing and classification of the EpiPen through Medicaid, the pharmaceutical company announced Friday.
Mylan, which came under fire this summer for systematically hiking the price of the life-saving device, at the same time allegedly improperly classified the EpiPen as a generic drug. That led Medicaid and Medicare to both overpay for the product.
Mylan said the settlement, after the government had said it improperly classified EpiPen as a generic drug, did not imply any admission of wrongdoing.
EpiPen maker Mylan agreed to pay $465 million in a settlement with federal regulators over its pricing practices
Mylan, the drug company that makes EpiPen, has been overcharging Medicare and Medicaid for years. But today the pharmaceutical company had to finally pay the piper. In a deal announced by the notorious price-gougers, Mylan will hand...
Mylan will pay $465 million to settle allegations that it overbilled Medicaid for its life-saving EpiPen allergy injection. The federal government says EpiPen is a branded drug, which means Mylan should have been paying a far higher...